Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Tablet Once Daily Compared With Placebo in Participants With Obesity or Overweight With and Without Type 2 Diabetes

NCT06972459 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT06972459
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06972459 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Tablet Once Daily Compared With Placebo in Participants With Obesity or Overweight With and Without Type 2 Diabetes
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Active, not recruiting
Start date
May 15, 2025
Completion date
August 31, 2027
Enrollment
800 (estimated)
Sites
80

Conditions

As the registry lists them; a condition with its own page is linked.

obesity, overweight